Cite
MLA Citation
Eugenio Mercuri et al.. “Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.” Lancet neurology, vol. 20, no. 10, 2021, pp. 832–841. http://access.bl.uk/ark:/81055/vdc_100144485644.0x000045